Lyell Immunopharma, Inc.

H.C. Wainwright reiterated a Buy rating with a $45 price target after updated safety data from the colorectal cancer program addressed previous concerns, while Citizens maintained a Market Outperform rating and a $34 price target, citing clinical progress and a favorable financial position following the establishment of a GI prophylaxis regimen.

Analysts remain conflicted on Lyell Immunopharma, with some expressing reservations about the company's clinical trajectory. The stock has declined over 11% in a single week, reflecting investor uncertainty about the pace and reliability of clinical advancements, and the company continues to post no actual revenue against analyst expectations.

InvestingPro analysis suggests LYEL appears undervalued at current trading levels around $13.32, and technical signals from both short- and long-term moving averages support a Strong Buy designation, with a projected 13.83% rise over the next three months and a potential price range reaching $16.48.

Analyst price targets vary dramatically — from $34 to $45 — while the stock trades near $13, signaling deep disagreement about intrinsic value. The high degree of risk acknowledged in Lyell's own regulatory filings, combined with expected EPS losses of -$2.03 per share, casts doubt on lofty valuation assumptions.

The November 2025 exclusive license agreement with Innovative Cellular Therapeutics Holdings grants Lyell rights to cell therapy product candidates outside mainland China, Taiwan, Macau, and Hong Kong, potentially broadening the company's pipeline and global commercial reach in a CAR-T cell therapy market projected to grow at a CAGR of 36.67% through 2034.

The registration of 1,100,000 shares for resale by ICT Holdings introduces meaningful dilution risk, as Lyell receives no proceeds from these sales. The selling stockholder's ability to offload shares freely onto the market could weigh on the stock price, particularly given the recent 11% weekly decline already observed.